Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology: Clinical practice guideline for social anxiety disorder (2021).

Asakura, Satoshi; Yoshinaga, Naoki; Yamada, Hisashi; Fujii, Yutaka; Mitsui, Nobuyuki; Kanai, Yoshihiro; Inoue, Takeshi; Shimizu, Eiji

Asakura, Satoshi; Yoshinaga, Naoki; Yamada, Hisashi; Fujii, Yutaka; Mitsui, Nobuyuki; Kanai, Yoshihiro; Inoue, Takeshi; Shimizu, Eiji.

Afiliación

Asakura S; Japanese Society of Anxiety and Related Disorders, Tokyo, Japan.
Yoshinaga N; Japanese Society of Neuropsychopharmacology, Tokyo, Japan.
Yamada H; Department of Psychiatry, Hokkaido University Graduate School of Medicine/Health Care Center, Hokkaido University, Sapporo, Japan.
Fujii Y; Japanese Society of Anxiety and Related Disorders, Tokyo, Japan.
Mitsui N; School of Nursing, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Kanai Y; Japanese Society of Anxiety and Related Disorders, Tokyo, Japan.
Inoue T; Japanese Society of Neuropsychopharmacology, Tokyo, Japan.
Shimizu E; Department of Neuropsychiatry, Hyogo College of Medicine, Nishinomiya, Japan.

Neuropsychopharmacol Rep ; 43(3): 288-309, 2023 09.

Article en En | MEDLINE | ID: mdl-37624975

Asunto(s)

Fobia Social; Adulto; Humanos; Ansiedad/terapia; Trastornos de Ansiedad/tratamiento farmacológico; Trastornos de Ansiedad/terapia; Terapia Cognitivo-Conductual; Pueblos del Este de Asia; Fobia Social/tratamiento farmacológico; Fobia Social/terapia; Japón; Ansiolíticos/uso terapéutico; Terapia Combinada

Palabras clave

Japan; anxiety disorders; practice guidelines; social anxiety disorders; treatment

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Fobia Social Tipo de estudio: Guideline / Prognostic_studies País/Región como asunto: Asia Idioma: En Revista: Neuropsychopharmacol Rep Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google